The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
Open Access
- 24 November 2022
- journal article
- review article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 15, 6427-6438
Abstract
Bruton’s tyrosine kinase (BTK) is a central signaling node in B cells. BTK inhibition has witnessed great success in the treatment of B-cell malignancies. Additionally, in the immune system, BTK is also a prominent component linking a wide variety of immune-related pathways. Therefore, more and more studies attempting to dissect the role of BTK in autoimmune and inflammation progression have emerged in recent years. In particular, BTK expression was also found to be elevated within the central nervous system (CNS) during neuroinflammation. BTK inhibitors are capable of crossing the blood–brain barrier rapidly to modulate B cell functions, attenuate microglial activities and affect NLRP3 inflammasome pathways within the CNS to improve the outcome of diseases. Thus, BTK inhibition appears to be a promising approach to modulate dysregulated inflammation in the CNS and alleviate destruction caused by excessive inflammatory responses. This review will summarize the immunomodulatory mechanisms in which BTK is involved in the development of neurological diseases and discuss the therapeutic potential of BTK inhibition for the treatment of neuroinflammatory pathology.Keywords
This publication has 109 references indexed in Scilit:
- Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase BtkNature Immunology, 2011
- TLR signaling and effector functions are intact in XLA neutrophilsClinical Immunology, 2010
- Bruton's tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cellsCellular Signalling, 2009
- Autophagy in MHC Class II Presentation: Sampling from WithinImmunity, 2007
- CCL5 evokes calcium signals in microglia through a kinase‐, phosphoinositide‐, and nucleotide‐dependent mechanismJournal of Neuroscience Research, 2006
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesThe Lancet Oncology, 2005
- Bruton's Tyrosine Kinase Is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor κB Activation by Toll-like Receptor 4Journal of Biological Chemistry, 2003
- Defective B cell development and function in Btk-deficient miceImmunity, 1995
- Mutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID MiceScience, 1993
- Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemiaCell, 1993